Monthly Archives: May 2016
-
Analyst: New company, shareholders will win with Biogen spin-off. But what’s in it for Biogen?
Biogen’s recently announced hemophilia spin-off should go well for the new company and its shareholders, an analyst predicts. But when done, Biogen ($ BIIB) itself could ...
